TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32662036

Group type: EXPERIMENTAL
Intervention: Current use of bisphosphonates
Number of subjects: 140202

Group type: EXPERIMENTAL
Intervention: Recent use of bisphosphonates
Number of subjects: 140202

Group type: EXPERIMENTAL
Intervention: Past use of bisphosphonates
Number of subjects: 140202

Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment duration less than 1 year
Number of subjects: 140202

Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment duration more than 1 year
Number of subjects: 140202

Group type: EXPERIMENTAL
Intervention: Stratified analysis by age, sex, and background cardiovascular risk
Number of subjects: 140202
Study: 36058419

Group type: EXPERIMENTAL
Intervention: LPS (0.8ng/kg, intravenously) + MP (40mg, orally)
Number of subjects: 8

Group type: COMPARATOR
Intervention: PBO + MP (40mg, orally)
Number of subjects: 8
Study: 33459805

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients
Number of subjects: 323

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients with vertebral fractures
Number of subjects: 323
Study: 35627702

Group type: EXPERIMENTAL
Intervention: Telephone intervention (n = 73)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Online intervention
Number of subjects: 458

Group type: COMPARATOR
Intervention: Written material (Control) (n = 81)
Number of subjects: 458
Study: 32430557

Group type: EXPERIMENTAL
Intervention: Community engagement and planning (CEP) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resources for services (RS) intervention
Number of subjects: 0
Study: 34592778

Group type: EXPERIMENTAL
Intervention: Bryonia alba 30c
Number of subjects: 2294

Group type: EXPERIMENTAL
Intervention: CVN01 nosode 30c
Number of subjects: 2294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2294

Group type: EXPERIMENTAL
Intervention: Arsenicum album 30c
Number of subjects: 2294

Group type: EXPERIMENTAL
Intervention: Combination (Arsenicum album 30c, Bryonia alba 30c, Gelsemium sempervirens 30c, and Influenzinum 30c)
Number of subjects: 2294

Group type: EXPERIMENTAL
Intervention: Camphora 1M
Number of subjects: 2294
Study: 34139801

Group type: EXPERIMENTAL
Intervention: Surgical remission of Cushing syndrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age and sex matched control persons
Number of subjects: 0
Study: 32514196

Group type: EXPERIMENTAL
Intervention: Short treatment regimen (9 to 11 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long treatment regimen (20 to 22 months)
Number of subjects: 0
Study: 32400032

Group type: EXPERIMENTAL
Intervention: SIALAC breastfeeding self-efficacy promoting programme
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 112
Study: 32901299

Group type: EXPERIMENTAL
Intervention: Pancreaticogastrostomy (PG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pancreaticojejunostomy (PJ)
Number of subjects: 60
Study: 35397508

Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg once daily)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 34706653

Group type: EXPERIMENTAL
Intervention: Prepaid cash card incentive
Number of subjects: 420

Group type: COMPARATOR
Intervention: Postpaid cash card incentive
Number of subjects: 420
Study: 35041809

Group type: EXPERIMENTAL
Intervention: 5% CBLH (single injection)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 10% CBLH (single injection)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 15% CBLH (single injection)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5% CBLH (4-time injections)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 10% CBLH (4-time injections)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 15% CBLH (4-time injections)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Phosphate buffered saline (1 injection)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Phosphate buffered saline (4 injections)
Number of subjects: 72
Study: 33172449

Group type: EXPERIMENTAL
Intervention: FDI criteria
Number of subjects: 0

Group type: COMPARATOR
Intervention: ICCMS criteria
Number of subjects: 0
Study: 33651729

Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Suspension Training (ST)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 118
Study: 33119068

Group type: EXPERIMENTAL
Intervention: 3AV (10 μg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1AV (20 µg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3AV
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1AV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3AV and 1AV
Number of subjects: 0
Study: 32089064

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4000 IU/day plus prenatal vitamins containing 400 IU vitamin D3)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 33779410

Group type: EXPERIMENTAL
Intervention: Gluteus maximus tenotomy (group 1)
Number of subjects: 158

Group type: COMPARATOR
Intervention: No gluteus maximus tenotomy (group 2)
Number of subjects: 158
Study: 32138782

Group type: EXPERIMENTAL
Intervention: Integrated management group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 34098984

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine, full course delivered by trained village health workers to all residents of compounds with reported clinical cases.
Number of subjects: 3738

Group type: COMPARATOR
Intervention: Control group screened for infection at the time of index case reporting, treated according to national guidelines.
Number of subjects: 3738

Group type: COMPARATOR
Intervention: Intervention arm (dihydroartemisinin-piperaquine) vs Control arm (screening and treatment).
Number of subjects: 3738
Study: 32895281

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (target Hb levels of 70-90 g/L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (target Hb levels of 100-120 g/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 0
Study: 35481441

Group type: EXPERIMENTAL
Intervention: Dietary 25-hydroxyvitamin D3 at 4.9 µg/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dietary 25-hydroxyvitamin D3 at 8.4 µg/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dietary 25-hydroxyvitamin D3 at 11.8 µg/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dietary 25-hydroxyvitamin D3 at approximately 5.0 µg/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dietary 25-hydroxyvitamin D3 at approximately 11.8 µg/kg
Number of subjects: 5
Study: 35347400

Group type: EXPERIMENTAL
Intervention: Immediate spa therapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual treatments (Control)
Number of subjects: 128
Study: 32534949

Group type: EXPERIMENTAL
Intervention: Tight Calorie Control guided by indirect calorimetry
Number of subjects: 417

Group type: COMPARATOR
Intervention: Standard calorie administration based on predictive equations (20-25 kcal/kg ideal body weight/day)
Number of subjects: 417
Study: 32095935

Group type: EXPERIMENTAL
Intervention: Endurance training + green tea extract supplementation (ET + GTE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Endurance training + placebo (ET + P)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No endurance training + placebo (P)
Number of subjects: 45
Study: 34017343

Group type: EXPERIMENTAL
Intervention: 1790GAHB vaccine (1.5/25 µg OAg/protein)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1790GAHB vaccine (0.06/1, 0.3/5, 1.5/25, 3/50, 6/100 µg OAg/protein)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36278294

Group type: EXPERIMENTAL
Intervention: TS-P1 45 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: CR-033P 90 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: CR-043P 90 mg
Number of subjects: 3
Study: 33368696

Group type: EXPERIMENTAL
Intervention: 11-point risk score incorporating mechanical ventilation, serum bilirubin, serum creatinine, and donor age
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Risk scores above 3 points
Number of subjects: 1156
Study: 33583253

Group type: EXPERIMENTAL
Intervention: Combined exercise (MIX)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Virtual reality balance training (VR)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Traditional balance training (BT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Waitlist control group (CON)
Number of subjects: 64
Study: 34973935

Group type: EXPERIMENTAL
Intervention: Recombinant FSH administered at 20:00 h
Number of subjects: 105

Group type: COMPARATOR
Intervention: GnRH antagonist administered at 08:00 h
Number of subjects: 105
Study: 34086608

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with limited deep sclerectomy (LDS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Trabeculectomy alone
Number of subjects: 68
Study: 32940642

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/L of α-MSH treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 35714103

Group type: EXPERIMENTAL
Intervention: Personalized Support for Progress (PSP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 32286232

Group type: EXPERIMENTAL
Intervention: 3-month internet-based intervention group (n=55)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Wait-list control group (n=50)
Number of subjects: 105
Study: 36468983

Group type: EXPERIMENTAL
Intervention: SNRI-Duloxetine therapy at a dose of 60 mg per day for 8 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Trimebutine therapy at a dose of 600 mg per day
Number of subjects: 61
Study: 34619162

Group type: EXPERIMENTAL
Intervention: Real TSST
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: VR-TSST
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo TSST
Number of subjects: 68
Study: 36107424

Group type: EXPERIMENTAL
Intervention: Self-sampled mouth-rinsing fluid (saliva sampling [SAL] with pooled PCR) plus nasal rapid antigen self-test (RAgT) (group 1)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Self-sampled mouth-rinsing fluid (SAL) only (group 2)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Nasal rapid antigen self-test (RAgT) only (group 3)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Overall participation rates
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 PCR tests
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Weekly participation rates
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Probability of SARS-CoV-2 introduction into DCC
Number of subjects: 452
Study: 33677193

Group type: EXPERIMENTAL
Intervention: MO (optimized original map)
Number of subjects: 30

Group type: COMPARATOR
Intervention: MC- (map minus C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: MT- (map minus T)
Number of subjects: 30

Group type: COMPARATOR
Intervention: MT+ (map plus T)
Number of subjects: 30
Study: 32479140

Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: secukinumab
Number of subjects: 0
Study: 34784820

Group type: EXPERIMENTAL
Intervention: Functional Strength Training (FST)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Control (Physical Education classes)
Number of subjects: 266
Study: 34087225

Group type: EXPERIMENTAL
Intervention: COSMOS intervention (multicomponent intervention including staff training in communication, pain treatment, medication review, organization of activities, and safety) for 4 months
Number of subjects: 723

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: COSMOS intervention
Number of subjects: 723
Study: 36357536

Group type: EXPERIMENTAL
Intervention: Ritualized action
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control action
Number of subjects: 268

Group type: COMPARATOR
Intervention: Neutral (no-activity)
Number of subjects: 268
Study: 33081825

Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 300

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 300
Study: 35793927

Group type: EXPERIMENTAL
Intervention: Cochlear implantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34376321

Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 24
Study: 36438274

Group type: EXPERIMENTAL
Intervention: 8-hour indoor clubbing event with no masks, no social distance, maximum room capacity, and ventilation
Number of subjects: 4400

Group type: COMPARATOR
Intervention: Control group asked not to go to the club
Number of subjects: 4400
Study: 33846151

Group type: EXPERIMENTAL
Intervention: Anticoagulation plus graduated compression stockings (European class II, 23‐32 mm Hg compression) worn for a median of 18 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anticoagulation (standard of care)
Number of subjects: 0
Study: 36072909

Group type: EXPERIMENTAL
Intervention: Pharmacopuncture therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 0
Study: 33652910

Group type: EXPERIMENTAL
Intervention: dGTE+ (400 mg·d‐1 EGCG, 50 mg·d‐1 quercetin, 150 mg·d‐1 α-lipoic acid)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: dGTE+
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 34668304

Group type: EXPERIMENTAL
Intervention: CAD/CAM titanium abutments bonded onto titanium bases (Ti-Base)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Individualized one-piece CAD/CAM titanium abutments
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 24
Study: 37409838

Group type: EXPERIMENTAL
Intervention: Propofol (1 mg kg ‐1 bolus followed by 4 mg kg ‐1 h ‐1 infusion)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 µg kg ‐1 followed by 2 µg kg ‐1 h‐1 infusion)
Number of subjects: 64
Study: 33568005

Group type: EXPERIMENTAL
Intervention: Imipramine 25 mg and solifenacin 5–10 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 33252951

Group type: EXPERIMENTAL
Intervention: Eban intervention
Number of subjects: 91
Study: 35168636

Group type: EXPERIMENTAL
Intervention: Date palm capsule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33592211

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided management
Number of subjects: 221

Group type: COMPARATOR
Intervention: Non-ultrasound-guided management
Number of subjects: 221
Study: 32976523

Group type: EXPERIMENTAL
Intervention: L-carnitine infusion (28mg/kg) with Intralipid (20%, 90mL/h)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intralipid (20%, 90mL/h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (CON)
Number of subjects: 8
Study: 34173051

Group type: EXPERIMENTAL
Intervention: Deep Convolutional Neural Network (CNN) model (YOLO) for diagnosing interproximal caries lesions
Number of subjects: 1000
Study: 34376533

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant (first-line)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant (second-line)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant (first-line, primary resistance to ET)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant (first-line, visceral disease)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant (second-line, visceral disease)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant (both subgroups)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (first-line)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (second-line)
Number of subjects: 265
Study: 35640636

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen
Number of subjects: 587
Study: 34664662

Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenvatinib 18 mg/day
Number of subjects: 0
Study: 33002283

Group type: EXPERIMENTAL
Intervention: 585-nm Q-switched Nd: YAG laser and 4% hydroquinone cream
Number of subjects: 21

Group type: COMPARATOR
Intervention: 4% hydroquinone cream alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 585-nm Q-switched Nd: YAG laser
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 21
Study: 35218685

Group type: EXPERIMENTAL
Intervention: Herbal mouthwash with payayor (Clinacanthus nutans Lindau)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Herbal mouthwash with fingerroot (Boesenbergia rotunda)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline with sodium bicarbonate (control)
Number of subjects: 120
Study: 34833666

Group type: EXPERIMENTAL
Intervention: FES-assisted cycling
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Volitional cycling (VOL)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No-intervention control (CON)
Number of subjects: 39
Study: 32403115

Group type: EXPERIMENTAL
Intervention: Immediate iron therapy
Number of subjects: 239

Group type: COMPARATOR
Intervention: Delayed iron therapy (28-day delay)
Number of subjects: 239
Study: 35470195

Group type: EXPERIMENTAL
Intervention: Spinal manual therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroid nerve root injections
Number of subjects: 0
Study: 33495294

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 32940092

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with natural orifice specimen extraction (NOSE)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Traditional laparoscopy
Number of subjects: 92
Study: 35226756

Group type: EXPERIMENTAL
Intervention: solution-focused psychotherapy (n=97)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: short-term psychodynamic psychotherapy (n=101)
Number of subjects: 326

Group type: COMPARATOR
Intervention: long-term psychodynamic psychotherapy (n=128)
Number of subjects: 326
Study: 32015285

Group type: EXPERIMENTAL
Intervention: J-pouch
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Side-to-end anastomosis
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Straight anastomosis
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Cleveland Clinic Colorectal Cancer Quality of Life Questionnaire
Number of subjects: 190
Study: 35072639

Group type: EXPERIMENTAL
Intervention: Sugar intervention video (3.42 minutes long)
Number of subjects: 4013
Study: 32853740

Group type: EXPERIMENTAL
Intervention: Ministernotomy
Number of subjects: 100
Study: 34284726

Group type: EXPERIMENTAL
Intervention: Elastic band resistance training (3 times per week for 12 weeks)
Number of subjects: 63
Study: 32038011

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair with omentoplasty (16 patients, 80%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open repair (4 patients, 20%)
Number of subjects: 20
Study: 35609292

Group type: EXPERIMENTAL
Intervention: Randomization within 0-30 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomization within 31-60 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomization within 61-90 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomization within 91-120 minutes
Number of subjects: 0
Study: 33607803

Group type: EXPERIMENTAL
Intervention: therapy of 'combination 3 methods progression'
Number of subjects: 60

Group type: COMPARATOR
Intervention: usual rehabilitation care
Number of subjects: 60
Study: 32703182

Group type: EXPERIMENTAL
Intervention: Gluteal turnover flap
Number of subjects: 160

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 160
Study: 35451636

Group type: EXPERIMENTAL
Intervention: Forced diuresis using furosemide 1 mg/kg (GII)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (GI)
Number of subjects: 148
Study: 32049634

Group type: EXPERIMENTAL
Intervention: Low-energy total diet replacement (TDR)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standardized dietetic care
Number of subjects: 90
Study: 33113211

Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) 2 days/week at 90% 1RM for 12 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (CG) received two introductory training sessions and encouragement to train independently
Number of subjects: 48

Group type: COMPARATOR
Intervention: Both TG and CG
Number of subjects: 48
Study: 32937837

Group type: EXPERIMENTAL
Intervention: Group A (no treatment)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group B (antibiotics before implantation)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group C (implants after functional endoscopic sinus surgery)
Number of subjects: 120

Group type: COMPARATOR
Intervention: MOD (distance between maxillary sinus ostium and sinus floor)
Number of subjects: 120
Study: 35477616

Group type: EXPERIMENTAL
Intervention: REL-1017 25 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: REL-1017 50 mg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 34463696

Group type: EXPERIMENTAL
Intervention: Low-normal Pao2 target (8 to 12 kPa), n = 205
Number of subjects: 574

Group type: COMPARATOR
Intervention: High-normal Pao2 target (14 to 18 kPa), n = 195
Number of subjects: 574
Study: 35145043

Group type: EXPERIMENTAL
Intervention: 14-day bismuth-based quadruple therapy (n=102)
Number of subjects: 782

Group type: COMPARATOR
Intervention: 14-day metronidazole-intensified triple therapy (n=99)
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 782
Study: 35130447

Group type: EXPERIMENTAL
Intervention: Flexible clinical trial designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-clinical screening of drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel compounds
Number of subjects: 0
Study: 32063382

Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences (ACE) survey
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Household dysfunction
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Health-harming behaviours
Number of subjects: 1760